Boston Collaborative Drug Surveillance Program
Impact in
- Internal Medicine top 10%
- Pharmacology top 10%
- Inflammatory mediators and NSAID effects
- Drug-Induced Adverse Reactions
Papers in
-
- Pharmaceutical Practices and Patient Outcomes 13
- Toxicology 12
- Top scholars
- Hershel JickSusan S. JickChristoph MeierJames A. KayeLaura E. DerbyRaymond G. SchliengerDavid J. GreenblattMichael Bodmer
- Journals
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (49 papers)British Journal of Clinical Pharmacology (25 papers)The Lancet (22 papers)Clinical Epidemiology (19 papers)Drug Safety (17 papers)
- Partner nations
- United StatesSwitzerlandUnited Kingdom
In The Last Decade
Boston Collaborative Drug Surveillance Program
418 papers receiving 20.9k citations
Peers
Comparison fields: 5 of 188
- Internal Medicine 661
- Pharmacology 2.8k
- Psychiatry and Mental health 2.2k
- Toxicology 520
- Endocrinology, Diabetes and Metabolism 2.1k
Countries citing scholars working at Boston Collaborative Drug Surveillance Program
This map shows the geographic impact of research produced by authors working at Boston Collaborative Drug Surveillance Program. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Boston Collaborative Drug Surveillance Program with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boston Collaborative Drug Surveillance Program more than expected).
Fields of papers published by authors at Boston Collaborative Drug Surveillance Program
This network shows the impact of papers affiliated with Boston Collaborative Drug Surveillance Program at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Boston Collaborative Drug Surveillance Program at the time of their publication.
About Boston Collaborative Drug Surveillance Program
In recent decades, authors affiliated with Boston Collaborative Drug Surveillance Program have published 524 papers, which have received a total of 28.5k indexed citations . Scholars at this organization have produced 13 papers in Geriatrics and Gerontology, 12 papers in Toxicology, 29 papers in Pharmacology, 10 papers in Internal Medicine and 44 papers in Pharmacology on the topics of Pharmaceutical studies and practices (17 papers), Inflammatory mediators and NSAID effects (17 papers), Drug-Induced Adverse Reactions (17 papers), Drug-Induced Hepatotoxicity and Protection (16 papers), Metabolism, Diabetes, and Cancer (15 papers), Lipoproteins and Cardiovascular Health (15 papers), Reproductive Health and Contraception (13 papers) and Pharmaceutical Practices and Patient Outcomes (13 papers). Their work is cited by papers focused on Internal Medicine (661 citations), Pharmacology (2.8k citations), Psychiatry and Mental health (2.2k citations), Toxicology (520 citations) and Endocrinology, Diabetes and Metabolism (2.1k citations). Authors at Boston Collaborative Drug Surveillance Program collaborate with scholars in United States, Switzerland and United Kingdom and have published in prestigious journals including Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, British Journal of Clinical Pharmacology, The Lancet, Clinical Epidemiology and Drug Safety. Some of Boston Collaborative Drug Surveillance Program's most productive authors include Hershel Jick, Susan S. Jick, Christoph Meier, James A. Kaye, Christoph Meier, Laura E. Derby, Raymond G. Schlienger, David J. Greenblatt, Michael Bodmer and Russell R. Miller.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.